Siemens PET/CT Receives FDA Clearance

Article

Siemens announced FDA has cleared features associated with their new Biograph mCT positron emission tomography/computed tomography scanner, which the company unveiled at RSNA in November 2011.

Siemens Healthcare announced FDA has cleared features associated with their new Biograph mCT positron emission tomography/computed tomography scanner, which the company unveiled at the RSNA meeting in November 2011.

The Biograph mCT provides precise measurement of metabolic processes and data qualification, as well as cardiac blood flow. The PET quantification allows physician to more precisely characterize cancer lesions, and the ability to measure myocardial blood flow allows for more accurate assessment of multi-vessel disease, the company said. In neurology, noninvasive assessment of the brain can potentially improve the diagnosis and management of patients who present with signs of dementia, according to the company.

The Biograph mCT incorporates Siemens’ OptisoHD (High Definition) detector system, which features a fine volumetric resolution of 87 mm. Also included is Time of Flight (TOF) and HD-PET, ensuring fast, precise images with minimum radiation dose, according to Siemens. The Quanti-QC daily system normalization can be performed overnight, calibrating and tuning the system to the right specifications.

The system also features a patient handling system to address differential deflection, the Auto Cardiac Registration that automatically aligns CT and PET heart images and reduces variability between users, as well as Siemens Molecular and Anatomical Registration Technologies, which the company said was a new form of attenuation correction for neurological images that doesn’t require CT data.

The Biograph mCT is expected to ship in May 2012.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.